Pluristem Therapeutics Inc. (PSTI) - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 12, 2019, regarding an event that occurred on August 8, 2019. Pluristem Therapeutics Inc. is a Nevada corporation with its principal executive offices in Haifa, Israel. The company's common stock trades on the Nasdaq Capital Market under the symbol "PSTI."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The material change reported is the restoration of the company's compliance with Nasdaq listing requirements. Specifically, the Nasdaq staff determined that the closing bid price of the Company's common stock had been at $1.00 per share or greater for at least 10 consecutive business days.
Guidance, Outlook, and Risks
The filing does not contain management guidance, future outlook, or specific risk factors. The primary contingency addressed was the risk of delisting due to low stock price, which has been resolved as the company regained compliance with Nasdaq Listing Rule 5550(a)(2).
Key Facts for Investor Verification
- The company regained compliance with Nasdaq minimum bid price requirements as of August 8, 2019.
- Compliance was achieved by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days.
- The report was signed by Chen Franco-Yehuda, Chief Financial Officer, on August 12, 2019.
- No financial data or operational updates are included in this specific filing.